Literature DB >> 10944144

Dexrazoxane in anthracycline extravasation.

S W Langer, M Sehested, P B Jensen, J Buter, G Giaccone.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944144

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.

Authors:  Joris W F Uges; Albert M Vollaard; Erik B Wilms; Rolf E Brouwer
Journal:  Int J Clin Oncol       Date:  2006-12-25       Impact factor: 3.402

Review 2.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.

Authors:  Sana M Salih; Ashley K Ringelstetter; Mazin Z Elsarrag; David H Abbott; Elon C Roti Roti
Journal:  Biol Reprod       Date:  2015-01-21       Impact factor: 4.285

Review 4.  Treatment of anthracycline extravasations using dexrazoxane.

Authors:  D Conde-Estévez; J Mateu-de Antonio
Journal:  Clin Transl Oncol       Date:  2013-08-15       Impact factor: 3.405

5.  Extravasational side effects of cytotoxic drugs: A preventable catastrophe.

Authors:  Jagdeep S Thakur; C G S Chauhan; Vijay K Diwana; Dayal C Chauhan; Anamika Thakur
Journal:  Indian J Plast Surg       Date:  2008-07

6.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

Review 7.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.